Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01987986 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy
A Phase 2 study of Edematous Fibrosclerotic Panniculopathy (EFP), sponsored by Endo Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 10
- Study locations
NCT01987986: Completed Phase 2 study of Edematous Fibrosclerotic Panniculopathy (EFP), sponsored by Endo Pharmaceuticals.
NCT01987986 is a Phase 2 study of Edematous Fibrosclerotic Panniculopathy (EFP) that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 150 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01987986, a Phase 2 study of Edematous Fibrosclerotic Panniculopathy (EFP), has completed, sponsored by Endo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 10
- Study locations
Study Summary
To assess the safety and effectiveness of repeat doses of AA4500 in the treatment of edematous fibrosclerotic panniculopathy (EFP) commonly known as cellulite in adult women.
Primary Outcome
Investigators assessment of aesthetic improvement (I-GAIS) scores ranged from 3 to -1 as follows: 3 (very much improved), 2 (much improved), 1 (improved), 0 (no change), -1 (worse).
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Collagenase Clostridium Histolyticum
Study Locations (10)
California
- Dermatology Cosmetic Laser Medical Associates of La Jolla - San Diego
- ATS Clinical Research - Santa Monica
Florida
- Dermatology Research Institute - Coral Gables
- Kenneth Beer, MD PA - West Palm Beach
New York
- Sadick Research Group - New York
- Stony Brook University Medical Center - Stony Brook
Missouri
- Mercy Health Research - Washington
Tennessee
- Tennessee Clinical Research Center - Nashville
Virginia
- Charlottesville Dermatology - Charlottesville
Washington
- Premier Clinical Research - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
What the finished NCT01987986 record still lists
NCT01987986 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher).
The record links to 1 condition, with Edematous Fibrosclerotic Panniculopathy (EFP) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01987986 lists 10 locations in 7 states (California, Florida, New York).
Frequently Asked Questions
What is clinical trial NCT01987986 about?
NCT01987986 is a clinical study titled "A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy". To assess the safety and effectiveness of repeat doses of AA4500 in the treatment of edematous fibrosclerotic panniculopathy (EFP) commonly known as cellulite in adult women.
What is the current status of trial NCT01987986?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2013-10. Estimated completion is 2014-08.
What conditions does trial NCT01987986 study?
This clinical trial studies the following conditions: Edematous Fibrosclerotic Panniculopathy (EFP).
What interventions are being tested in trial NCT01987986?
The interventions under investigation include: Placebo (BIOLOGICAL), Collagenase Clostridium Histolyticum (BIOLOGICAL).
Who is sponsoring clinical trial NCT01987986?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01987986 being conducted?
This trial has 10 study locations across California, Florida, Missouri, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01987986's enrollment target sits among peer trials
150 455th of 2000 higher than 1,510 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia